Signal
FDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordable
The U.S. Food and Drug Administration today announced another major step in its initiative to streamline the development of biosimilar medicines, which are like “generic” versions of biologic drugs.
rssx
fierce_pharma
Evidence locked
Today's free sample is only available for the edition's flagship signal.
Evidence preview
- FDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordablefda_press_releases
- The FDA's newest draft guidance reinforces its previous commitment to streamlining biosimilar drug development by rem...Fierce Pharma (All)
- FDA takes major step to streamline biosimilar medicines, which are like “generic” versions of biologic drugs. New dra...US_FDA